AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2020
May 27, 2020
30604_dirs_2020-05-27_740ee22a-f5a6-4b73-8721-ef5db2d9a320.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-05-26
Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-05-26 | Common Stock | M | 18365 | $1.05 | Acquired | 264268 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-05-26 | Stock Option (Right to Buy) | $1.05 | M | 18365 | Disposed | 2029-12-17 | Common Stock (18365) | Direct |
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3